SCHEMBL467478

SCHEMBL467478

CC1CCN(C2CCN(c3ccc(-n4nc(N)nc4N)cc3F)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 4/20 0.42
GAA P10253 4/20 0.40
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HTT P42858 1/20 0.38
INSR P06213 1/20 0.37
KDR P35968 1/20 0.37
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
NR4A1 P22736 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KCNH2 Q12809 2/20 0.33
MAPT P10636 2/20 0.33
HTR1A P08908 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL467659 0.90 AXL (0.49) AXLALDH1A1INSRKDRMAPT
SCHEMBL467696 0.89 AXL (0.43) AXLALDH1A1INSRKDRKCNH2
SCHEMBL27769653 0.87 AXL (0.42) AXLALDH1A1INSRKDRMAPT
SCHEMBL467833 0.87 AXL (0.47) AXLSMN1; SMN2ALDH1A1INSRKDR
SCHEMBL467749 0.87 AXL (0.40) AXLINSRKDRKCNH2HTR1A
SCHEMBL30090809 0.85 AXL (0.47) AXLGAAALDH1A1INSRKDR
SCHEMBL27790975 0.85 AXL (0.47) AXLGAAALDH1A1INSRKDR
SCHEMBL467792 0.84 AXL (0.44) AXLINSRKDR
SCHEMBL467601 0.81 FLT3 (0.36) AXLGAAALDH1A1HTTINSR
SCHEMBL27769731 0.80 RAD52 (0.35) AXLGAAINSRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101622246-A Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors RIGEL PHARMACEUTICALS INC 2010-01-06 CN claimed
CN-116075303-A Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator 卑尔根生物股份公司 2023-05-05 CN disclosed
CN-115916344-A AXL inhibitors for antiviral therapy 卑尔根生物股份公司 2023-04-04 CN disclosed
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
CN-101622246-A Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors RIGEL PHARMACEUTICALS INC 2010-01-06 CN disclosed